The clinical performance of CD63‐UCNP‐LFIA was evaluated by quantifying CD63‐positive uEVs from healthy individuals (n = 30), patients with BPH (n = 50) and those with BlCa (n = 62). Here, CD63 is linked to bladder transitional cell carcinoma.